September 16, 2022
Hepatologist Naim Alkhouri and Endocrinologist Scott Isaacs join Ken Cusi and Roger Green to discuss drug choices prescribers can make TODAY for patients with Type 2 Diabetes Mellitus and obesity that have positive impact on Fatty Liver disease.
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
This episode From the Vault comes from Season 3, Episode 39.4. Ian Rowe’s decision curve model does an excellent job of modeling the success rate and cost effectiveness of modeling early NASH diagnosis. However, as Louise Campbell points out, simply getting the patient diagnosed does not mean therapeutic success, which has implications for the early diagnosis model and broader patient management issues.
The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. Respectively, Pamela Danagher (Terns Pharma), Jerry Mabary (Chronwell) and Caitlin Schneider (Sonic Incytes) join Jörn Schattenberg and Roger Green to explore questions around biopsy, patient centricity, NITs versus “tests” and combination therapy.
Surfing NASH presents an exclusive interview with Dean Tai, Co-Founder and CSO of global-leading AI digital pathology provider HistoIndex. Dean joins Co-Surfers Jörn Schattenberg and Roger Green to discuss the application and compelling results of AI-assisted histologic assessment of Phase 2 trials on aldafermin and resmetirom.
Surfing NASH highlights key moments from its coverage of a historic NASH-TAG conference. In this conversation, Donna Cryer and Roger Green share impressions from the regulatory viewpoint.
Surfing NASH highlights key moments from its coverage of a historic NASH-TAG conference. In this conversation, Naim Alkhouri, Amy Articolo, Jörn Schattenberg and Roger Green explore key takeaways, insights on the F3 population and using AI-assisted assessment to improve those therapeutic efficacy.
Surfing NASH highlights key moments from its coverage of a historic NASH-TAG conference. In this conversation, Scott Friedman and Rachel Zayas join Louise Campbell, Jörn Schattenberg and Roger Green to discuss their impressions and most compelling takeaways from a pivotal event.
Surfing NASH highlights key moments from its coverage of a historic NASH-TAG conference. In this conversation, Stephen Harrison and Mazen Noureddin join Jörn Schattenberg and Roger Green to discuss NITs, clinical trial design and addressing the “indeterminate zones.”
Hepatology Researcher and Key Opinion Leader Stephen Harrison discussed results of his 2021 publication in the Journal of Hepatology that
